Johns Hopkins

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, March 27, 2024
Malignancy, Colitis, Survival, BioNTech, Patient, Lung, City, Standard of care, Quality of life, Fungal infection, Aspergillosis, Nationwide, Clinical trial, Bone marrow, Melanoma, Aspergillus fumigatus, Therapy, Human, Psoriasis, Partnership, World Health Organization, Coccidioides, Safety, Clutch (eggs), University, Kidney, Amphotericin B, Neoplasm, Research, Data monitoring committee, Infection, Skin, Vanderbilt University Medical Center, Hospital, Immunodeficiency, FDA, Critical, Element, Toxicity, IL-17A, Brain, Conference call, Conference, Johns Hopkins, Nephrotoxicity, Docetaxel, Serum, Inflammation, Mouse, Mortality, Fusarium, Bangladesh Technical Education Board, Pharmaceutical industry

BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.

Key Points: 
  • Aspergillus fumigatus is also included in the FDA qualified designation list of pathogens that pose a serious and life-threatening risk.
  • Revenue for 2023 was $1.1 million, which was generated from the Company’s research collaborations with BioNTech SE and Genentech Inc.
  • Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022.
  • Matinas will host a conference call and webcast today beginning at 4:30 p.m. Eastern time.

Leading Biometric Identify Verification & Authentication Firm authID Inc. Appoints Kunal Mehta to its Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
GTM, Organization, Johns Hopkins, Growth, Micro Focus, George Washington University, Software, Management information system, Infoblox, VMware, MHS, MBA, Marketing, TCV (investment firm), Enablement, Bain, B2B, Information system, Bain & Company

DENVER, March 26, 2024 (GLOBE NEWSWIRE) -- authID.ai [Nasdaq: AUID], a leading provider of innovative biometric identity verification and authentication solutions, today announced the appointment of Kunal Mehta to its Board of Directors, effective immediately. Mehta, a partner at Bain & Company, adds deep expertise in strategic growth areas targeted by authID: market expansion, go-to-market (GTM) strategy, and operational efficiency.

Key Points: 
  • Mehta, a partner at Bain & Company, adds deep expertise in strategic growth areas targeted by authID: market expansion, go-to-market (GTM) strategy, and operational efficiency.
  • “Kunal led Revenue Operations, Marketing, and Enablement teams, gaining valuable expertise that can help authID scale.
  • I am honored to join the authID Board and look forward to helping drive the Company’s growth,” said Director Kunal Mehta.
  • Currently, Mehta consults with some of the leading private equity (PE) and PE-backed companies at Bain & Company.

Scene Health and CareFirst Expand Partnership for Medicaid Members

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Professional Services, Managed Care, Other Health, Health, General Health, Pharmaceutical, Health Insurance, Infectious Diseases, Insurance, Clinical Trials, Culture, Johns Hopkins, Entrepreneurship, Partnership, CareFirst BlueCross BlueShield, Patient, Prescription, Asthma, Quality, Medicaid, Multimedia, Medicine, Hypertension, Pharmaceutical industry

Scene Health (Scene) and CareFirst BlueCross BlueShield (CareFirst), one of the country’s largest not-for-profit healthcare organizations, are proud to announce the expansion of their partnership.

Key Points: 
  • Scene Health (Scene) and CareFirst BlueCross BlueShield (CareFirst), one of the country’s largest not-for-profit healthcare organizations, are proud to announce the expansion of their partnership.
  • “Our partnership with Scene has helped deepen our understanding of the real-life experiences and challenges members were facing,” said Mike Rapach, President and CEO of CareFirst Community Health Plan Maryland (CHPMD).
  • “We are grateful for five years of outstanding partnership with CareFirst BlueCross BlueShield of Maryland’s Medicaid team.
  • “Innovations such as Scene Health's services seamlessly coordinated with other CareFirst health services, benefits, and rich network coverage are critical for us to improve the overall health and quality of care for our members."

Research Team Progresses to Final Phase in NIH Competition, Pioneering Autonomic Neuromodulation to Expand Applications for Spinal Stimulation

Retrieved on: 
Thursday, March 21, 2024
Kessler Institute for Rehabilitation, Research, Blood pressure, Reward, Health, TIM, Applied Physics Laboratory, Reynolds Center, Johns Hopkins, SPARC, Learning, Caregiver, News, Rehabilitation, University, Doctor of Philosophy, MD, Quality of life, NIH, Peripheral, Kessler Foundation, Competition, Tetraplegia, Autonomic nervous system, Mobility, Safety, University of Louisville, Neurostimulation, Self-management, Dysautonomia, Bangladesh Technical Education Board, Select Medical, Common Fund for Commodities, Pharmaceutical industry

EAST HANOVER, N.J., March 21, 2024 /PRNewswire/ -- Marking significant progress towards improving the lives of individuals with spinal cord injuries, Kessler Foundation, University of Louisville, and John Hopkins Applied Physics Laboratory (with the support of Medtronic) have collaboratively won the $1,000,000 prize for Phase 2 of the Neuromod Prize for their project titled, "Neuromodulation of the lumbosacral spinal cord for improvement of autonomic function after spinal cord injury." With this win, the team advances to compete for the Phase 3 prize pool of $5 million.

Key Points: 
  • With this win, the team advances to compete for the Phase 3 prize pool of $5 million.
  • Phase 1 called for innovative therapy concepts and development plans, leading to Phase 2's proof-of-concept studies by the eight selected teams.
  • On February 27, 2024, the NIH announced the four Phase 2 victors, marking a breakthrough moment in neuromodulation research.
  • "Most importantly, what we are learning and sharing about neuromodulation through this Competition will influence new approaches to treating other types of disabling autonomic dysfunction."

Operation Homefront Announces 2024 Military Child of the Year® Award Recipients

Retrieved on: 
Wednesday, March 13, 2024
Online, Impossible Foods, Carnival Cruise Line, National Guard, Johns Hopkins, Caesars Entertainment, SAN, School, University, Coast guard, PNC, Air force, Operation Homefront, RTX, Procter & Gamble, Parent, Space force, Navy, Army, Nursing

SAN ANTONIO, March 13, 2024 /PRNewswire-PRWeb/ -- Seven exceptional military children excelling in academics, community involvement, and peer leadership have a new award to add to their list: Operation Homefront Military Child of the Year®. The national nonprofit, whose mission is to build strong, stable, and secure military families, announced recipients of its 2024 premier award, following a nationwide search to identify and celebrate outstanding military children, which garnered more than 700 nominations.

Key Points: 
  • Now in its 16th year, the Military Child of the Year® Award celebrates the remarkable influence these extraordinary young individuals have on their families, schools, and communities.
  • SAN ANTONIO, March 13, 2024 /PRNewswire-PRWeb/ -- Seven exceptional military children excelling in academics, community involvement, and peer leadership have a new award to add to their list: Operation Homefront Military Child of the Year®.
  • The national nonprofit, whose mission is to build strong, stable, and secure military families, announced recipients of its 2024 premier award, following a nationwide search to identify and celebrate outstanding military children, which garnered more than 700 nominations.
  • This year's Military Child of the Year® Award recipients have moved a combined 37 times and lived through 247 months of deployments.

ScreenPoint Medical Deploys Transpara® Breast AI at Johns Hopkins to Improve Cancer Detection

Retrieved on: 
Tuesday, March 12, 2024
Research, 2D, Johns Hopkins, Radiology, Patient, National Cancer Institute, 3D, Cancer, Mammography, Workflow, MDR, Breast cancer, Workload, FDA, European, Health, Medical imaging

BALTIMORE, March 12, 2024 /PRNewswire/ -- ScreenPoint Medical, announced today that its industry leading Transpara Breast AI is available to improve cancer detection for Johns Hopkins breast cancer screening patients. Transpara assists radiologists with the reading of 2D and 3D mammography exams, providing a 'second pair' of eyes to help detect cancers earlier and reduce recall rates. 

Key Points: 
  • BALTIMORE, March 12, 2024 /PRNewswire/ -- ScreenPoint Medical , announced today that its industry leading Transpara Breast AI is available to improve cancer detection for Johns Hopkins breast cancer screening patients.
  • The Johns Hopkins Kimmel Cancer Center was one of the first to be recognized by the National Cancer Institute as a "Center of Excellence."
  • Across Johns Hopkins, the breast imaging services team conducts more than 77,000 breast imaging exams and 5,000 interventional procedures each year.
  • The ScreenPoint customer success team worked closely with both clinical and IT teams at Johns Hopkins to install Transpara Breast AI to support patient care at 7 locations.

ScreenPoint Medical Deploys Transpara® Breast AI at Johns Hopkins to Improve Cancer Detection

Retrieved on: 
Tuesday, March 12, 2024
Research, 2D, Johns Hopkins, Radiology, Patient, National Cancer Institute, 3D, Cancer, Mammography, Workflow, MDR, Breast cancer, Workload, FDA, European, Health, Medical imaging

BALTIMORE, March 12, 2024 /PRNewswire/ -- ScreenPoint Medical, announced today that its industry leading Transpara Breast AI is available to improve cancer detection for Johns Hopkins breast cancer screening patients. Transpara assists radiologists with the reading of 2D and 3D mammography exams, providing a 'second pair' of eyes to help detect cancers earlier and reduce recall rates. 

Key Points: 
  • BALTIMORE, March 12, 2024 /PRNewswire/ -- ScreenPoint Medical , announced today that its industry leading Transpara Breast AI is available to improve cancer detection for Johns Hopkins breast cancer screening patients.
  • The Johns Hopkins Kimmel Cancer Center was one of the first to be recognized by the National Cancer Institute as a "Center of Excellence."
  • Across Johns Hopkins, the breast imaging services team conducts more than 77,000 breast imaging exams and 5,000 interventional procedures each year.
  • The ScreenPoint customer success team worked closely with both clinical and IT teams at Johns Hopkins to install Transpara Breast AI to support patient care at 7 locations.

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Retrieved on: 
Monday, February 26, 2024
Infection, Bangladesh Technical Education Board, Division, Amphotericin B, Palliative care, Recurrence, University, Doctor of Philosophy, Malignancy, Nationwide, Physician, City, Azole, Hospital, Cryptococcosis, Nephrotoxicity, Skin, Aspergillosis, Fusarium, Lung, Fungal infection, Johns Hopkins, Vanderbilt University Medical Center, LNC, Coccidioides, Patient, Coccidioidomycosis, Histoplasmosis, Brain, Pharmaceutical industry

BEDMINSTER, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today provided an update from its ongoing Compassionate/Expanded Use Access Program (the “Program”) with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B.

Key Points: 
  • Treatment with MAT2203 was well tolerated and led to favorable clinical and radiological response and we did not observe any renal toxicity.
  • 5 additional patients have shown objective improvement in clinical markers and are continuing treatment with MAT2203 as planned.
  • 2 patients transitioned to palliative care shortly after starting therapy with MAT2203 because of unanticipated progression of their malignant disease.
  • “We continue to be excited about the ongoing, consistent positive clinical impact of MAT2203, seen in these extremely ill patients,” said Theresa Matkovits, PhD, Chief Development Officer at Matinas .

Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year and Welcomes Two New SAB Members

Retrieved on: 
Friday, March 8, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Software, General Health, Science, Data Management, Clinical Trials, Community health, GSK, AbbVie, Huntington's disease, University, Mathematics, Emory University, Behavioral neurology, Pathology, School, Alzheimer's disease, Johnson & Johnson, Drug design, Gold, Bristol Myers Squibb, Johns Hopkins, Disorder, Psychiatry, Derek, UCB, Computer science, American Neurological Association, Asha, Parkinson's Foundation, Conference, Chemistry, Safety, Amelioration, CNS, Behavioural sciences, Medical school, MD, Neurology, Patient, Florida College, Disease, Publication, DRS, Pharmaceutical industry

Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.

Key Points: 
  • Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.
  • ASHA-091 restores normal mitochondrial function and has demonstrated disease modifying efficacy as a functional cure in preclinical disease models.
  • In preparation for clinical transition, Asha has appointed Dr. Michael Gold and Dr. Allan Levey to their Scientific Advisory Board.
  • Their expertise comes at a pivotal moment for Asha as we transition our first-in-class lead programs designed using our PRISM™ technology to clinical trials.

Panoramic Health Launches Scientific Advisory Board to Accelerate Innovation in Kidney Care

Retrieved on: 
Thursday, March 7, 2024
Doctor of Philosophy, Person, Dialysis, Health, University, Acute kidney injury, Health policy, Kidney disease, Diagnosis, Literature, Belding, Michigan, ASN, Bangladesh Technical Education Board, Chronic kidney disease, National Kidney Foundation, NIH, Johns Hopkins, National Academy of Medicine, UNC, Partnership, American Kidney Fund, CKD, Kidney, Biomarker, Prognosis, MPH, Research, Division, Public policy, Population health, FDA, National academy, Entrepreneurship, Society, Patient, Physician, Pharmaceutical industry

TEMPE, Ariz., March 7, 2024 /PRNewswire/ -- Today, Panoramic Health, kidney care's leading integrated provider group, is proud to announce the establishment of its Scientific Advisory Board, a distinguished group of clinical leaders and research experts committed to advancing kidney care innovation. With a focus on uncovering and delivering cutting-edge treatments for patients with kidney disease, the advisory board will play a crucial role in guiding Panoramic Science, the company's clinical research division.

Key Points: 
  • TEMPE, Ariz., March 7, 2024 /PRNewswire/ -- Today, Panoramic Health, kidney care's leading integrated provider group, is proud to announce the establishment of its Scientific Advisory Board, a distinguished group of clinical leaders and research experts committed to advancing kidney care innovation.
  • "At Panoramic Health, we are dedicated to redefining the standard of kidney care through innovation and collaboration," said Dr. Rajiv Poduval, Co-Founder and Executive Chairman of Panoramic Health.
  • "Our Scientific Advisory Board brings together exceptional expertise that will drive our efforts to enhance patient care and transform the evolving landscape of kidney disease treatment.
  • Panoramic Health leadership team members serving on the advisory board include:
    The establishment of the Scientific Advisory Board underscores Panoramic Health's commitment to driving innovation and improving the lives of patients with kidney disease.